93 related articles for article (PubMed ID: 20096281)
1. Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors.
Liu CQ; Wong SL; Leung FP; Tian XY; Lau CW; Lu L; Yao X; Chen ZY; Yao T; Huang Y
Eur J Pharmacol; 2010 Apr; 632(1-3):45-51. PubMed ID: 20096281
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase.
Liu CQ; Leung FP; Wong SL; Wong WT; Lau CW; Lu L; Yao X; Yao T; Huang Y
Biochem Pharmacol; 2009 Aug; 78(4):374-81. PubMed ID: 19409373
[TBL] [Abstract][Full Text] [Related]
3. Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor.
Liu CQ; Leung FP; Lee VW; Lau CW; Yao X; Lu L; Huang Y
Eur J Pharmacol; 2008 Aug; 590(1-3):250-4. PubMed ID: 18554583
[TBL] [Abstract][Full Text] [Related]
4. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
5. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon kappa-opioid receptor stimulation in the rat heart.
Bian JS; Zhang WM; Pei JM; Wong TM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1065-70. PubMed ID: 10688624
[TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
7. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
Kumari M; Cover PO; Poyser RH; Buckingham JC
Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
[TBL] [Abstract][Full Text] [Related]
9. Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle.
Challiss RA; Adams D; Mistry R; Nicholson CD
Br J Pharmacol; 1998 May; 124(1):47-54. PubMed ID: 9630342
[TBL] [Abstract][Full Text] [Related]
10. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
11. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
13. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery.
Kobayashi K; Murata T; Hori M; Ozaki H
Eur J Pharmacol; 2011 Jun; 660(2-3):375-80. PubMed ID: 21463619
[TBL] [Abstract][Full Text] [Related]
15. The effect of the protein phosphatases inhibitor cantharidin on beta-adrenoceptor-mediated vasorelaxation.
Knapp J; Bokník P; Linck B; Lüss H; Müller FU; Nacke P; Neumann J; Vahlensieck U; Schmitz W
Br J Pharmacol; 1997 Feb; 120(3):421-8. PubMed ID: 9031745
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
[TBL] [Abstract][Full Text] [Related]
18. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide.
Tesfamariam B
J Hypertens; 1994 Jan; 12(1):41-7. PubMed ID: 8157943
[TBL] [Abstract][Full Text] [Related]
19. Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition.
Lo YC; Tsou HH; Lin RJ; Wu DC; Wu BN; Lin YT; Chen IJ
Life Sci; 2005 Jan; 76(8):931-44. PubMed ID: 15589969
[TBL] [Abstract][Full Text] [Related]
20. Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
Ransjö M; Fredholm BB; Lerner UH
Bone Miner; 1988 Jan; 3(3):225-34. PubMed ID: 2462948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
